{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-25-000128","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.220088+00:00","generated_at":"2026-05-17T01:47:35.145745+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M","bullets":["Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.","Gross margin improved to 76.6% from 74.9% YoY; adjusted EBITDA $9.2M vs $6.5M.","Raised full-year revenue guidance to at least $222.8M (≥19% growth); gross margin reaffirmed 73-75%.","FDA PDUFA for Avance Nerve Graft BLA extended to Dec 5, 2025; AAHS and ASRM issued position statements recognizing nerve allografts.","Added 18.1M covered lives in 2025; commercial payer coverage now over 64%."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-25-000128","json":"https://secwatch.observer/filing/0000805928-25-000128.json","markdown":"https://secwatch.observer/filing/0000805928-25-000128.md","text":"https://secwatch.observer/filing/0000805928-25-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000128/0000805928-25-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000128/axgn-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:47:35.145745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}